Work

Randomized phase 2 study to evaluate the efficacy and safety of silevertinib in combination with temozolomide in newly diagnosed patients with EGFRvIII-positive IDHwt MGMT unmethylated glioblastoma.

Year: 2026

Type: conference-abstract

Study design: Study Protocol

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.tps2098

Authors: Patrick Y. Wen, Fabio M. Iwamoto, Rupesh Kotecha, Sergey Yurasov, Julio Hajdenberg, Vinay K. Puduvalli

Institutions: Dana-Farber Cancer Institute, Columbia University Irving Medical Center, Baptist Hospital of Miami, Baptist Health South Florida, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162683121

Cites:

Cited by: 1

Related to: